Skip to main content
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD risk
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
ESC backs SGLT2 inhibitor plus GLP-1 in diabetes with high CVD risk
User login
Username
Password
Reset your password
Concept
Lead
score
Type 2 Diabetes Mellitus
1
1
Clinical Guidelines
0
0.78
Chronic Kidney Disease
0
0.51
Renal Failure
0
0.46
GLP-1 Receptor Agonist
0
0.99
Heart Failure (HF)
0
0.43
Cardiovascular Risk Management
0
0.97
Europe
0
0.26
Heart
0
0.26
Receptors
0
0.26
SGLT2 Inhibitor
0
0.98
Hemoglobin A1c
0
0.18
Renal Disease
0
0.16
Hemoglobin
0
0.13
Biomarker
0
0.07
Blood
0
0.07
Cardiovascular disease
0
0.95
Diabetes Mellitus
0
0.07
Epidemiology
0
0.07
Jobs
0
0.07
Kidney
0
0.07
Metabolism
0
0.07
Specialty
Lead
score
Cardiology
1
1
Diabetes & Endocrinology
0
0.9
Family Medicine/Primary Care
0
0.8
Internal Medicine
0
0.7
Edit Tags